Quantcast
Last updated on April 20, 2014 at 14:04 EDT

Latest Oxford BioMedica plc Stories

2013-05-09 04:21:22

OXFORD, England, May 9, 2013 /PRNewswire/ -- -- UshStat(R)video selected to showcase theme of "Life-changing Research" -- Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, today announces an update from the 2013 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) held in Seattle, Washington (USA) on 5-9 May 2013. The ARVO annual meeting is the largest gathering of eye and...

2012-08-07 22:21:13

OXFORD, England, August 8, 2012 /PRNewswire/ -- -- Treatment of final RetinoStat(R)patient cohort underway -- Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, and its partner Sanofi (EURONEXT: SAN and NYSE: SNY) today announce a positive interim review of the RetinoStat(R) Phase I study in neovascular "wet" age-related macular degeneration (AMD) and the StarGen(TM) Phase I/IIa study in Stargardt...

2012-07-22 22:20:39

OXFORD, England, July 23, 2012 /PRNewswire/ -- -- Award of US$125,000 will support a second clinical site in Paris, France -- Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, today announces that the US non-profit organisation, the Foundation Fighting Blindness (FFB), has granted an award of US$125,000 to the Company via its translational research arm, the Foundation Fighting Blindness Clinical...

2011-10-31 02:00:00

OXFORD, England, October 31, 2011 /PRNewswire/ -- - Research and development agreement signed with Mayo Clinic - Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, today announces that it has entered into a research and development collaboration with Mayo Clinic, Rochester (USA) to develop a novel gene therapy for the treatment of chronic glaucoma. Under the terms of the agreement, Mayo Clinic and...

2011-10-18 01:00:00

OXFORD, England, October 18, 2011 /PRNewswire/ -- -- Third ocular product partnered with Sanofi approved to enter clinical development -- Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, today announces that the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for the Phase I/IIa clinical development of UshStat(R), a novel gene-based treatment for Usher...

2011-06-22 01:00:00

OXFORD, England, June 22, 2011 /PRNewswire/ -- - RetinoStat(R) Progress in Phase I Study in Wet Age-Related Macular Degeneration Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), a leading gene therapy company, today announces that the first dose level of RetinoStat(R) is safe and well-tolerated at one month following treatment. RetinoStat(R) is a novel gene-based treatment for neovascular "wet" age-related macular degeneration (AMD), designed and...

2011-05-23 01:00:00

OXFORD, England, May 23, 2011 /PRNewswire-FirstCall/ -- - Six-Month Data From Third Cohort Presented at ASGCT 14th Annual Meeting - - Highest Efficacy Results to Date With 43% Average Motor Function Improvement - Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), a leading gene therapy company, announces that new data from the on-going Phase I/II trial of ProSavin(R) for the treatment of Parkinson's disease (PD) were presented at the American Society of...

2011-03-15 02:00:00

OXFORD, England, March 15, 2011 /PRNewswire-FirstCall/ -- - Immune Response Surrogate Algorithm Shownto be a Significant Predictor of Clinical Benefit Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), a leading gene therapy company, today announces that further analyses of the TroVax(R) Renal Immunotherapy Survival Trial ("TRIST"), a randomised, double-blind, placebo-controlled Phase III study, have been accepted for publication in Cancer Immunology,...

2008-08-15 09:01:04

GeneThera, Inc. (PINKSHEETS: GTHR) announced today that has tendered a new offer for the acquisition of Oxford Biomedica Plc. Commenting on the news GeneThera Chairman Dr. Tony Milici, M.D., Ph.D. stated, "We carefully evaluated Oxford Biomedica's present situation from a management, scientific and equity prospective. Based on our analysis, we decided to resubmit our previous rejected offer at a higher price per share. We strongly believe that GeneThera may indeed be in the position, by...